Search clinical trials for: Rivaroxaban (BAY 59-7939, Xarelto) in ODT form

Total 26 results

Bayer
Janssen Research & Development, LLC

Completed

Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 10 mg in Japanese Healthy Male Adult Subjects

Clinical Pharmacology

Japan
Bayer
Janssen Research & Development, LLC

Completed

Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on the Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 15 mg in Japanese Healthy Male Adult Subjects

Clinical Pharmacology

Japan
Bayer

Completed

Bioequivalence Study of Rivaroxaban

Embolism, Atrial Fibrillation and Venous Thrombosis

Japan
Bayer

Completed

Bioequivalence Study of Rivaroxaban in Japanese Healthy Adult Male Subjects

Embolism, Atrial Fibrillation and Venous Thrombosis

Japan
Bayer
Janssen Research & Development, LLC

Completed

Xarelto on Prevention of Stroke and Non-Central Nervous Systemic Embolism in Renally Impaired Korean Patients With Non-valvular Atrial Fibrillation (XARENAL)

Non-valvular Atrial Fibrillation (NVAF)

Korea, Republic of
Bayer
Janssen Research & Development, LLC

Active, not recruiting

A Study to Evaluate the Safety and Effectiveness of Rivaroxaban (Xarelto) for Prevention of Stroke and Systemic Embolism in Indian Patients With Non-valvular Atrial Fibrillation (NVAF) (XARIN)

Non-valvular Atrial Fibrillation (NVAF)

India
Bayer
Janssen Research & Development, LLC

Completed

A Non-interventional Study on Xarelto for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active Cancer (COSIMO)

Venous Thrombosis and Pulmonary Embolism

Italy, Germany, United Kingdom, France, Belgium, Canada, Netherlands, Spain, Denmark, Australia
Bayer
Janssen Scientific Affairs, LLC

Completed

Xarelto on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in China: A Non-interventional Study (XASSURE)

Stroke

China
Bayer
Janssen Research & Development, LLC

Completed

Xarelto for Real Life Anticoagulation in Pulmonary Embolism (PE) in China (XAPEC)

Pulmonary Embolism

China
Bayer
Janssen Research & Development, LLC

Completed

Xarelto Evidence in Real Life of Patients' Preference and Satisfaction Study (X-PRESS)

Atrial Fibrillation

Taiwan
Janssen Research & Development, LLC
Bayer

Completed

A Pharmacokinetics, Pharmacodynamics and Safety Study of Single Dose of Rivaroxaban in Participants With End-Stage Renal Disease (ESRD) on Maintenance Hemodialysis

End-Stage Renal Disease

United States
Bayer

Completed

Study to Compare the Effectiveness of Rivaroxaban (Xarelto) Versus Low-molecular-weight Heparin (LMWH) and Phenprocoumon for the Treatment and Secondary Prevention of Venous Thromboembolism in Routine Clinical Practice in Germany

Venous Thromboembolism

Germany
Bayer
Janssen Research & Development, LLC

Completed

BAY 59-7939 (Xarelto, SPAF), Non Interventional Studies

Atrial Fibrillation

Germany
Janssen Research & Development, LLC

Terminated

A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection (PREVENT-HD)

Coronavirus Disease 2019 (COVID-19)

United States
Bayer
Janssen Pharmaceutical Companies (formerly Johnson & Johnson Pharmaceutical...

Recruiting

An Observational Study to Learn More About How Safe Treatment With Rivaroxaban is in Children in Japan With Venous Thromboembolism

Venous Thromboembolism

Japan
Bayer
Janssen Research & Development, LLC

Completed

Xarelto for VTE Prophylaxis After Hip or Knee Arthroplasty (XAMOS)

Venous Thromboembolism

Switzerland, China, Slovakia, France, Germany, Hungary, Korea, Republic of, Singapore, South Africa, Spain, Sweden, Philippines, Australia, Austria, Colombia, Czech Republic, Estonia, Hong Kong, Italy, Latvia, Lebanon, Lithuania, Macedonia... and more
Xijing Hospital

Unknown

Treatment of Rivaroxaban Versus Aspirin for Non-disabling Cerebrovascular Events (TRACE)

Ischemic Stroke | TIA

China
Bayer
Janssen Scientific Affairs, LLC

Completed

Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism) (EinsteinChoice)

Thrombosis | Venous Thrombosis | Thromboembolism | Venous Thromboembolism | Pulmonary Embolism

Belgium, France, China, Switzerland, New Zealand, South Africa, Hungary, United States, Canada, Australia, Netherlands, Spain, Russian Federation, Austria, Mexico, Taiwan, Brazil, Czechia, Denmark, Germany, Israel, Italy, Korea, Republic... and more
Bayer

Active, not recruiting

Study to Learn More About the Safety and Effectiveness of Rivaroxaban (Xarelto) When Given Together With Acetylsalicylic Acid to Indian People With Narrowing of the Arteries of the Heart (CAD) and/or With Reduced Blood Flow in the Arteries of the Legs and Arms With Symptoms (Symptomatic PAD)

Coronary Artery Disease (CAD) | Prevention of Atherothrombotic Events | Symptomatic Peripheral Artery Disease (Symptomatic PAD)

India
Bayer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study

Venous Thrombosis

United Kingdom, Belgium, France, Israel, Italy, Spain, China, Hong Kong, Korea, Republic of, United States, New Zealand, Poland, India, Hungary, Singapore, Canada, Australia, Netherlands, Austria, Switzerland, Brazil, Denmark, Germany, Norw... and more
Bayer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study

Pulmonary Embolism

United Kingdom, Belgium, France, Israel, Italy, Spain, China, Hong Kong, Switzerland, United States, New Zealand, Poland, India, Hungary, Singapore, Canada, Australia, Netherlands, Austria, Estonia, Thailand, Brazil, Germany, Korea, Republic... and more
Bayer

Completed

A Study to Collect Data on the Treatment Pattern of Xarelto + Acetylsalicylic Acid in the Routine Clinical Practice in Patients Who Are Suffering From a Condition That Narrows the Blood Vessels Supplying the Heart and / or a Condition That Most Commonly Narrows the Blood Vessel in the Legs (XATOC)

Coronary Artery Disease | Peripheral Artery Disease

Spain, Belgium, Italy, Korea, Republic of, Russian Federation, Taiwan, China, Colombia, Switzerland, Slovenia
Bayer
Janssen Research & Development, LLC

Completed

Venous Thromboembolism (VTE) Treatment Study in Japanese Pulmonary Embolism (PE) Patients

Pulmonary Embolism

Japan
Janssen Research & Development, LLC
Harvard Medical School (HMS and HSDM); Bayer; Duke Clinical Research Institute

Completed

A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome (GEMINI ACS 1)

Acute Coronary Syndrome

United States, France, Poland, Ukraine, Belgium, Spain, Argentina, Bulgaria, Russian Federation, Turkey, Japan, Canada, Netherlands, Korea, Republic of, Brazil, Australia, Hungary, Sweden, Czechia, Denmark
Centre Hospitalier Universitaire de Besancon

Recruiting

Screening Anal HPV Colonization in Men Sex Men Using Pre-exposure Prophylaxis for HIV (ANAPreP'HPV) (ANAPreP'HPV)

Pre-Exposure Prophylaxis

France
Rabin Medical Center

Unknown

Perfusion Computer Tomography: Imaging and Clinical Validation Following Reperfusion Therapy in Acute Ischaemic Stroke

Ischemic Stroke

Israel

Search clinical trials for: Rivaroxaban (BAY 59-7939, Xarelto) in ODT form

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Netherlands

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations